Events

EntityRisk Co-Founder and CEO Neal Masia, PhD, will speak in this Fast Facts session on how US Most-Favored-Nation (MFN) pricing reaches beyond US drug prices, reshaping global launch strategy and patient access. Joined by panelists from GSK and Insights & Impact, Neal will explore the "Accidental FX Trader" dynamic: how currency swings and conversion rules create US price-benchmark risks that traditional foreign exchange strategies can't hedge against.

EntityRisk Co-Founder and Chief Scientific Officer of EntityRisk and Chief Scientific Officer of the USC Schaeffer Center Darius Lakdawalla, PhD, will participate in this ISPOR Europe 2026 forum examining the value judgements embedded in how health economists measure "value." The session will explore competing methodological frameworks in health economic and outcomes research, the assumptions built into cost-effectiveness analysis, and how different analytic choices can lead to different conclusions about the value of medical technologies.

Devin Incerti, PhD, Head of Data Science at EntityRisk, will present on model validation at ISPOR.

Neal Masia, PhD, Co-Founder and CEO of EntityRisk, will speak at this ISPOR Fast Facts Session. This session will examine how shifting global health policies and fragmented regulatory environments are reshaping pharmaceutical R&D, market prioritization, and the consequential effects.

Neal Masia, PhD, Co-Founder and CEO of EntityRisk, will speak at this ISPOR Workshop. He will discuss when development-stage biotechs should implement HEOR capabilities and how these teams can maximize an organization's clinical and commercial impact.

Dana Goldman, PhD, Co-Founder and Scientific Advisor of EntityRisk and Director of the USC Schaeffer Center, will moderate the plenary to discuss the economic, regulatory, and long-term consequences of U.S. pharmaceutical policies in both the US and abroad.

Darius Lakdawalla, PhD, Co-Founder and Chief Scientific Officer of EntityRisk and Chief Scientific Officer of the USC Schaeffer Center, will participate as a speaker to discuss how U.S. drug policies are reshaping innovation, evidence, and access globally.

This issue panel will debate whose preferences should govern health technology adoption. Darius Lakdawalla, PhD, Co-Founder and Chief Scientific Officer of EntityRisk and Chief Scientific Officer of the USC Schaeffer Center, will present the case for incorporating individual-level risk preferences into value assessment and argue why such approaches may better align with welfare economics and decision-making.

Join EntityRisk and industry leaders for a discussion on how HEOR and Market Access professionals are navigating the evolving policy, access, and value landscapes.

Come visit us at Booth #805.